key: cord-0879569-380qpolg authors: Bastopcu, Murat title: Extensive Arterial Thrombus Following Discharge after a Covid-19 Infection date: 2020-12-14 journal: Ann Vasc Surg DOI: 10.1016/j.avsg.2020.11.008 sha: db8d6b438844294888638db4ebdaf296c8b96b65 doc_id: 879569 cord_uid: 380qpolg The novel coronavirus pandemic is associated with coagulopathy and an increased risk of thromboembolic events. A case of an extensive arterial thrombus in the left leg of a patient that occurred after discharge from Covid-19 pneumonia is described. Some patients may be under continued risk of thromboembolism after discharge and the value of extended thromboprophylaxis should be investigated. The novel coronavirus pandemic is associated with coagulopathy and an increased risk of thromboembolic events. 1, 2 Most reports of thromboembolism are venous; however, severe arterial thrombi are reported and can worsen the prognosis of Covid-19 patients. Below described is a case of an extensive arterial thrombus in the left leg of a patient that occurred after discharge from Covid-19 pneumonia. A 55-year-old male presented to the emergency department with malaise and shortness of breath. Patient history was remarkable only for diabetes mellitus on insulin treatment. He was evaluated for a Covid-19 infection. His lung computed tomography (CT) showed ground-glass opacities on both lungs (Fig. 1) , and the reverseetranscriptase polymerase chain reaction (RT-PCR) test was positive for Covid-19. The patient was admitted to the infectious diseases ward and started on chloroquine, favipiravir, meropenem, levofloxacin, intravenous methylprednisolone, and prophylactic anticoagulation, with a single dose daily enoxaparin. Initially, the patient was supported with oxygen via a face mask. The patient's oxygenation improved after 6 days, and he no longer required supplemental oxygen. The patient was discharged in one week, at which time, the second RT-PCR test returned negative for Covid-19. The patient discontinued his medications, including prophylactic lowemoleculare weight heparin, and was advised home isolation. Four days after discharge from the hospital, the patient presented to the emergency department with gradual onset pain and numbness on the left leg that started one day prior. On examination, the left lower extremity was cold, the distal foot appeared ischemic, and mottling of the skin was evident below the knee (Fig. 2) . Sensory loss below the knee and paralysis of the calf muscles were observed. All pulses in the left leg were absent. The patient corresponded to Rutherford Stage IIb for acute limb ischemia. Doppler ultrasound revealed acute thrombus in the main, superficial, and deep femoral arteries, anterior tibial, posterior tibial, and peroneal arteries. He was started on a heparin drip, and a CT scan was performed to assess the large vessels, which showed thrombus also in the left external iliac artery (Fig. 3) . No thrombus was evident in the patient's thoracic or abdominal aorta. No evidence of peripheral arterial disease was observed in the thrombosed or contralateral leg arteries, nor wall thickening associated with vessel wall inflammation could be seen in CT. D-dimer could not be measured as laboratory resources were limited in our remote hospital, and Ddimer tests were reserved for critical patients. His Creactive protein level was 251 mg/L, neutrophil-tolymphocyte ratio was 29.29, prothrombin time was 11.5 s. His electrocardiograms in the period of admission for pneumonia and emergency admission for acute limb ischemia showed normal sinus rhythm. His echocardiographic study did not show any valvular pathology, endocarditis, or a patent foramen ovale. Urgent thrombectomy was performed to the external iliac artery; main, deep, and superficial femoral arteries; and below-the-knee arteries with Fogarty catheters. Abundant thrombus was removed proximally and distally, restoring arterial flow. Heparin was continued after the operation. Discoloration, numbness, and pain receded in the calf and foot. The patient is followed up with paralysis of the foot, without a need for amputation. Coagulopathy associated with the novel coronavirus has been observed in the early months of the pandemic, and the addition of anticoagulation to the treatment of Covid-19 patients has been gamechanging. 1 Nevertheless, coagulopathy remains an essential problem in these patients. Markers of inflammation increase with the severity of disease, associated with worsened prognosis and thromboembolic complications. The proinflammatory cytokines that increase over the course of infection activate the coagulation cascade by multiple mechanisms, including increased expression of tissue factor and endothelial activation. 2,3 Critical patients are more prone to thromboembolic complications, while patients treated in the general wards are also under risk. Lodigiani et al. 4 reported a rate of 27.6% for thrombotic events in intensive care unit (ICU) patients, and a rate of 6.6% for general ward patients. Disease severity is associated with increased inflammation, but not all patients adhere to the same chronological progression or symptomatology, and some patients present with thromboembolism as their first symptom. 5, 6 The acute phase of the Covid-19 infection is associated with a cytokine storm and its resulting coagulopathy. Complications that arise later than the acute phase may result from a different mechanism. After the initial innate immune response with cytokines and monocyte activation, the transition to the adaptive immune response is an important step in Normally, acute arterial thrombosis arises in the setting of arterial atherosclerosis or cardiac diseases. With the novel coronavirus, patients can suffer from thrombosis in the absence of traditional risk factors for acute thromboembolism. 9 Arterial thromboembolism associated with Covid-19 infection can arise in the extremities, mesenteric arteries, or cerebral arteries, and thrombi can be present in multiple locations. 6 There are reports of lowerisk patients whose courses are complicated by arterial thrombosis. 10, 11 Thrombosis in Covid-19 can also be more extensive with higher associated limb loss and death. 12 In the retrospective cohort of Etkin et al., 6 the rate of limb loss was 18% in patients hospitalized with Covid-19 who developed arterial thromboembolism. With the increased risk of limb loss and thrombus burden in this patient group, it may be advisable to continue anticoagulation after discharge, weighing the risks of hemorrhage and the benefits of continued prophylaxis for highe risk patients. 13 Covid-19eassociated coagulopathy can cause thrombosis in the arterial circulation with poor outcomes. The risk of thromboembolic events continues after discharge from hospital. Patients recovering from the novel coronavirus infection should be followed up for thromboembolic complications, and the value of continued prophylactic anticoagulants should be investigated. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 COVID-19 associated coagulopathy and thrombotic complications The unique characteristics of COVID-19 coagulopathy Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in COVID-19 presenting as acute limb ischaemia Acute arterial thromboembolism in patients with COVID-19 in the New York City area The trinity of COVID-19: immunity, inflammation and intervention Immune response, inflammation, and the clinical spectrum of COVID-19 Early experience with arterial thromboembolic complications in patents with COVID-19 Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis COVID-19 related arterial coagulopathy Lower extremity arterial thrombosis associated with COVID-19 is characterized by greater thrombus burden and increased rate of amputation and death COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up Post-discharge thrombosis and hemorrhage in patients with COVID-19 No conflict of interest to declare. This research did not receive any specific grant from funding agencies in the public, commercial, or notfor-profit sectors.